TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
Bioventix plc
(“Bioventix” or the “Company”)
Board Appointment
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics is delighted to announce that it has appointed Joanne (Jo) Pisani to the Board, as an independent Non-Executive Director, with immediate effect. Jo will chair the Company’s Audit Committee.
Jo is a chartered engineer with a distinguished background in the Pharmaceutical, Life Sciences and Biotech sectors. She has held roles at GSK and BP in strategy, commercial and operational functions before working in strategic consultancy. She led PwC’s UK Pharmaceutical and Life Sciences practice, assisting clients with developing strategy, designing and implementing transformational change and completing M&A transactions.
Jo is a passionate supporter of critical public health issues, such as tackling dementia, rare diseases and anti-microbial resistance. She focuses on supporting charities, universities and business start-ups. She is chair of Birmingham’s Precision Health Technology Accelerator and also chairs the Advisory Board for London’s MedCity. She serves on the boards of the UK Dementia Research Institute, LifeArc, The RSA Group, London and Partners and Beacon. She is also a Non-Executive Director and strategic advisor to biotech companies in the UK, Finland and Spain
Ian Nicholson, Chairman, commented: “The Board is delighted to welcome Jo to Bioventix. She brings considerable leadership and strategic experience in Life Sciences and biotech businesses, large and small, that is highly relevant to Bioventix and the opportunities being addressed by the Company. I am confident that she will add considerable value to the Company.”
For further information please contact:
| Bioventix plc
Peter Harrison Bruce Hiscock |
Chief Executive Officer Chief Financial Officer |
Tel: 01252 728 001 |
| finnCap Ltd
Geoff Nash/Simon Hicks Alice Lane |
Corporate Finance ECM |
Tel: 020 7220 0500 |
Regulatory disclosures
INFORMATION REQUIRED UNDER RULE 17 AND SCHEDULE 2, PARAGRAPH (G) OF THE AIM RULES FOR COMPANIES (“AIM RULES”)
| Full name: | Joanne (Jo) Patra Pisani |
| Age: | 58 |
| Shareholding in the Company: | No shares held |
| Current directorships and partnerships: |
UK DRI Ltd Beacon: for rare diseases Ltd LAM Action LifeArc London & Partners Limited PHTA Ltd Ostique Limited Adora Digital Health Ltd Elem Biotech SL Aplagon Oy RSA (Holdings) Ltd MedCity Ltd
|
| Historic directorships and partnerships in previous 5 years: | Karoo CGT Limited
Pricewaterhouse Coopers LLP |
There is no further information to be disclosed in relation to the director appointment pursuant to Rule 17 and Schedule 2, paragraph (g) of the AIM Rules.
Bioventix plc
(“Bioventix” or the “Company”)
Director/PDMR Shareholdings and Issue of Equity
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, was notified on 18 May 2023 of the following transactions in its ordinary shares of 5 pence each (“Ordinary Shares”):
|
Director |
Role |
Options over Ordinary Shares exercised |
Ordinary Shares sold |
Average sale price per Ordinary Share |
Ordinary Shares subsequently held |
Percentage of issued share capital subsequently held |
|
Ian Nicholson |
Non-Executive Chairman |
1,638 |
1,638 |
3,651.53 |
13,000 |
0.2% |
The options over Ordinary Shares (“Options”) were exercised at a price of 1350 pence per Ordinary Share pursuant to the Company’s 2013 EMI Share Option Scheme, details of which can be found at www.bioventix.com. In addition, a current employee exercised 2,333 Options.
Issue of Equity
The Company has applied for 3,971 new Ordinary Shares to be admitted to trading on AIM (“Admission”). It is expected that Admission will occur and that dealings will commence in the new Ordinary Shares on 25 May 2023. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.
The total number of Ordinary Shares in issue following Admission will be 5,219,656 and the Company holds no shares in treasury. Therefore, the total number of Ordinary Shares with voting rights in the Company will be 5,219,656.
The above figure of 5,219,656 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Bioventix under the FCA’s Disclosure Guidance and Transparency Rules.
For further information please contact:
|
Bioventix plc Peter Harrison Bruce Hiscock |
Chief Executive Officer Chief Financial Officer |
Tel: 01252 728 001 |
|
finnCap Ltd Geoff Nash/Simon Hicks Alice Lane |
Corporate Finance ECM |
Tel: 020 7220 0500 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1 |
Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated (“PCA”) |
|||||
|
a) |
Name |
Ian Nicholson |
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
Chairman |
||||
|
b) |
Initial notification/Amendment |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Bioventix plc |
||||
|
b) |
LEI |
213800225MHX7LZQY108 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary Shares of 5 pence each |
||||
|
Identification code |
GB00B4QVDF07 |
|||||
|
b) |
Nature of the transaction |
Exercise of Options over Ordinary Shares |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information: · Aggregated volume · Price |
See 4(c) |
||||
|
e) |
Date of the transaction |
18 May 2023 |
||||
|
f) |
Place of the transaction |
Off market transaction |
||||
|
1 |
Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated (“PCA”) |
|||||
|
a) |
Name |
Ian Nicholson |
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
Chairman |
||||
|
b) |
Initial notification/Amendment |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Bioventix plc |
||||
|
b) |
LEI |
213800225MHX7LZQY108 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary Shares of 5 pence each |
||||
|
Identification code |
GB00B4QVDF07 |
|||||
|
b) |
Nature of the transaction |
Sale of Ordinary Shares |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information: · Aggregated volume · Price |
See 4(c) |
||||
|
e) |
Date of the transaction |
18 May 2023 |
||||
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON)
|
||||
Bioventix plc
(“Bioventix” or “the Company”)
Director Dealing
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 24 April 2023 that on 24 April 2023 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 11 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at an average price of 3,823 pence per Ordinary Share (the “Purchase”). The Ordinary Shares were purchased under a dividend reinvestment plan (“DRIP”).
Following the Purchase, Bruce Hiscock has a beneficial interest in 761 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
For further information please contact:
|
Bioventix plc Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
|
finnCap Ltd Geoff Nash/Simon Hicks Alice Lane |
Corporate Finance ECM |
Tel: 020 7220 0500 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Bruce Hiscock |
|
2. |
Reason for the Notification |
|
|
a) |
Position/status |
Chief Financial Officer |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Bioventix Plc |
|
b) |
LEI |
213800225MHX7LZQY108 |
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary Shares of 5 pence each |
|
Identification code |
GB00B4QVDF07 |
|
|
b) |
Nature of the transaction |
Purchase of Ordinary Shares |
|
c) |
Price(s) and volume(s) |
11 Ordinary Shares 3,823 pence |
|
d) |
Aggregated information:
· Aggregated volume
· Price |
Purchase of 11 Ordinary Shares at 3,823 pence each |
|
e) |
Date of the transaction |
24 April 2023 |
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
Bioventix plc
(“Bioventix” or the “Company”)
Unaudited Interim Results for the six months ended 31 December 2022
Bioventix plc (BVXP) (“Bioventix” or “the Company”), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its unaudited interim results for the six-month period ended 31 December 2022.
Highlights
· Revenue up 25% to £5.9 million (2021: £4.7 million)
· Profit before tax up 27% to £4.5 million (2021: £3.6 million)
· Closing cash balances of £5.2 million (2021 £5.1 million)
· Interim dividend up 20% to 62p per share (2021: 52p)
CHAIRMAN AND CHIEF EXECUTIVE’S STATEMENT
Business review
Bioventix is pleased to report revenues for the half-year of £5.9 million (2021: £4.7 million). Sales of physical product have performed well and revenues from our vitamin D antibody and other core antibodies have all increased as anticipated.
Sales relating to troponin antibodies grew significantly once again during the period. The continued roll-out of high sensitivity troponin tests provides further encouragement for our future sales in this area.
Total profits before tax for the half-year were up 27% to £4.5 million (2021: £3.6 million). The cash balances at 31 December 2022 stood at £5.2 million (2021 £5.1 million).
Our research activities continue in line with the plans we described in our 2022 annual report.
We continue to await news and critical data from both of our partners in Oslo; on our secretoneurin project with CardiNor for enhancing cardiac diagnostics and on our amyloid beta project with Pre-Diagnostics in Alzheimer’s diagnostics. We hope to have more news on these two projects during 2023.
A considerable amount of our laboratory resource has been focused on the Tau biomarker which shows exciting potential in neurodegenerative diseases including Alzheimer’s disease. We continue to create new antibodies which will be subjected to assay development and validation using clinical samples at the world-renowned laboratory of Kaj Blennow and Henrik Zetterberg at the University of Gothenburg. Using a novel Bioventix antibody, our academic collaborators in Gothenburg have recently published data on a novel assay that detects “brain-derived” Tau in blood (Brain 2022: 00; 1-14). Brain-derived Tau levels in blood appear to mimic Tau levels in cerebral spinal fluid and could be a useful blood biomarker for neurodegeneration that occurs later in the Alzheimer’s disease pathway. Currently, the preferred candidate research biomarkers for early Alzheimer’s disease are phosphorylated forms of Tau (pTaus). We eagerly await more data from Gothenburg on the pTau antibodies developed by us and delivered to Gothenburg in 2022. We will be providing additional antibodies from the Bioventix pipeline for further evaluation in Gothenburg later in 2023. We are delighted with the continuing development of this collaboration and the outlook remains exciting.
We are also pleased with our progress on the continued development of our industrial pollution exposure assay. Our prototype lateral flow test for pyrene in industrial worker’s urine is due to feature in a new field trial at a UK industrial site during Q2.2023. The results from the device and phone-app will again be correlated with parallel samples analysed by a central health and safety laboratory. Important feedback from the trial will be gained and is likely to prompt additional modifications to the phone-app camera reader system before more field trials are carried out in 2023 and 2024.
Forthcoming changes to both the UK Corporation Tax structure in respect of Research and Development and the headline rate of Corporation Tax will have an impact on our future reported earnings and cash flows. Nevertheless, we will endeavour to follow our established dividend policy and for the period under review, the Board is pleased to announce an interim dividend of 62 pence per share which represents a 20% increase on the interim dividend paid last year (52 pence per share). The shares will be marked ex-dividend on the 6th April 2023 and the dividend will be paid on 21st April 2023 to shareholders on the register at close of business on 11th April 2023.
In conclusion, after the difficulties experienced during the pandemic, we are pleased to see a solid performance of our core business and look forward to this continuing over the remainder of the year. We remain optimistic about our troponin revenues and the success of these high sensitivity troponin products around the world and we look forward to reporting further progress in the second half of the year.
For further information please contact:
| Bioventix plc
Peter Harrison Bruce Hiscock |
Chief Executive Officer Chief Financial Officer |
Tel: 01252 728 001 |
| finnCap Ltd
Geoff Nash/Simon Hicks Alice Lane |
Corporate Finance ECM |
Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
BIOVENTIX PLC
STATEMENT OF COMPREHENSIVE INCOME
for the six month period ended 31 December 2022
|
Unaudited ended 31 Dec 2022 |
|
Unaudited ended 31 Dec 2021 |
|
|
£
|
|
£
|
|
|
TURNOVER |
5,895,137 |
4,730,570 |
|
|
Cost of sales |
(431,051) |
(388,205) |
|
|
GROSS PROFIT |
5,464,086 |
4,342,365 |
|
|
Administrative expenses |
(874,661) |
(669,107) |
|
|
Share option charge |
(123,442) |
(129,873) |
|
|
Difference on foreign exchange |
4,868 |
10,565 |
|
|
Research & development tax credit adjustment |
9,674 |
5,583 |
|
|
OPERATING PROFIT |
4,480,525 |
3,559,533 |
|
|
Interest receivable |
35,342 |
2,657 |
|
|
PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION |
4,515,867 |
3,562,190 |
|
|
Tax on profit on ordinary activities |
(785,488) |
(574,380) |
|
|
PROFIT FOR THE FINANCIAL PERIOD |
3,730,379 |
2,987,810 |
|
|
Earnings per share for the period: |
|
|
|
|
Basic |
71.61p |
57.35p |
|
|
Diluted |
70.90p |
56.79p |
BIOVENTIX PLC
STATEMENT OF FINANCIAL POSITION
as at 31 December 2022
|
|
Unaudited |
|
Unaudited 31 Dec 2021 |
|
|
|
|
|
||
|
£ |
|
£ |
||
|
FIXED ASSETS |
|
|||
|
|
|
|||
|
|
|
|||
|
Tangible fixed assets |
|
640,219 |
779,003 |
|
|
Investments |
|
610,039 |
610,039 |
|
|
|
|
|
||
|
1,250,258 |
1,389,042 |
|||
|
CURRENT ASSETS |
||||
|
Stocks |
525,656 |
375,163 |
||
|
Debtors |
4,785,883 |
3,813,882 |
||
|
Cash at bank and in hand |
5,148,376 |
5,050,769 |
||
|
|
|
|
||
|
10,459,915 |
9,239,814 |
|||
|
CREDITORS: amounts falling due within one year |
(1,221,885) |
(836,475) |
||
|
|
|
|||
|
NET CURRENT ASSETS |
9,238,030 |
8,403,339 |
||
|
TOTAL ASSETS LESS CURRENT LIABILITIES |
10,488,288 |
9,792,381 |
||
|
PROVISIONS FOR LIABILITIES |
||||
|
Deferred Tax |
(22,649) |
(63,717) |
||
|
NET ASSETS
|
10,465,639 |
9,728,664 |
||
|
CAPITAL AND RESERVES |
||||
|
Called up share capital |
260,467 |
260,467 |
||
|
Share premium account |
1,332,472 |
1,332,471 |
||
|
Capital redemption reserve |
1,231 |
1,231 |
||
|
Profit and loss account |
8,871,469 |
8,134,495 |
||
|
SHAREHOLDERS’ FUNDS |
10,465,639 |
9,728,664 |
||
BIOVENTIX PLC
STATEMENT OF CASH FLOWS
for the six month period ended 31 December 2022
|
Unaudited 31 Dec 2022 |
|
Unaudited 31 Dec 2021 |
||
|
£ |
|
£ |
||
|
CASHFLOW FROM OPERATING ACTIVITIES |
|
|||
|
Cash flows from operating activities Profit for the financial period |
|
3,730,379 |
2,987,810 |
|
|
Depreciation of tangible fixed assets |
|
64,733 |
68,034 |
|
|
Interest received |
|
(35,342) |
(2,657) |
|
|
Taxation charge |
|
785,488 |
574,380 |
|
|
Decrease / (increase) in stocks |
|
(63,841) |
(42,705) |
|
|
Decrease / (increase) in debtors |
|
438,834 |
812,085 |
|
|
(Decrease) /increase in creditors |
|
(95,049) |
(212,127) |
|
|
Corporation tax (paid) |
|
(741,344) |
(548,916) |
|
|
Share option charge |
|
123,442 |
129,873 |
|
|
Net cash generated from operating activities |
4,206,300 |
3,765,777 |
||
|
|
||||
|
Cash flows from investing activities |
|
|||
|
Purchase of tangible fixed assets |
(10,583) |
(3,317) |
||
|
Interest received |
35,342 |
2,657 |
||
|
Net cash from investing activities |
24,759 |
(660) |
||
|
Cash flows from financing activities |
||||
|
Issue of ordinary shares |
– |
– |
||
|
Movement on share premium account |
– |
– |
||
|
Dividends paid |
(5,209,333) |
(5,209,333) |
||
|
Net cash used in financing activities |
(5,209,333) |
(5,209,333) |
||
|
Cash and cash equivalents at the beginning of the period |
6,126,650 |
6,494,985 |
||
|
|
||||
|
Cash and cash equivalents at the end of the period |
5,148,376 |
5,050,769 |
||
|
|
|
|||
|
Cash and cash equivalents at the end of the period comprise: |
||||
|
Cash at bank and in hand |
5,148,376 |
5,050,769 |
||
BIOVENTIX PLC
Notes to the financial information
1. While the interim financial information has been prepared using the company’s accounting policies and in accordance with Financial Reporting Standard 102, the announcement does not itself contain sufficient information to comply with Financial Reporting Standard 102.
2. This interim financial statement has not been audited or reviewed by the auditors.
3. The accounting policies which were used in the preparation of this interim financial information were as follows:
|
3.1 |
Basis of preparation of financial statements |
|
|
The financial statements have been prepared under the historical cost convention and in accordance with FRS 102. |
|
3.2 |
Revenue |
|
|
•Turnover is recognised for product supplied or services rendered to the extent that it is probable that the economic benefits will flow to the Company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria determine when turnover will be recognised: •Direct sales are recognised at the date of dispatch. •Subcontracted R & D income is recognised based upon the stage of completion at the period end. •Annual licence revenue is recognised, in full, based upon the date of the invoice, and royalties are accrued over the period to which they relate. Revenue is recognised based on the returns and notifications received from customers and in the event that subsequent adjustments are identified, they are recognised in the period in which they are identified. |
BIOVENTIX PLC
Notes to the financial information
|
3.3 |
Tangible fixed assets and depreciation |
||||||
|
Tangible fixed assets are stated at cost less depreciation. Depreciation is not charged on freehold land. Depreciation on other tangible fixed assets is provided at rates calculated to write off the cost of those assets, less their estimated residual value, over their expected useful lives on the following bases: |
|||||||
|
|
|||||||
|
Freehold property |
‑ |
2% straight line |
|||||
|
Plant and equipment |
‑ |
25% reducing balance |
|||||
|
Motor Vehicles |
‑ |
25% straight line |
|||||
|
Equipment |
‑ |
25% straight line
|
|||||
|
3.4 |
Valuation of investments |
|
|
Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of comprehensive income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment. |
||
|
3.5 |
Stocks |
|
|
Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss. |
||
|
3.6 |
Debtors |
|
|
|
||
|
Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment. |
||
|
|
||
|
|
3.7 |
Cash and cash equivalents |
|
|
||
|
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than twelve months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value. In the Statement of cash flows, cash and cash equivalents are shown net of bank overdrafts that are repayable on demand and form an integral part of the Company’s cash management. |
||
|
|
||
|
|
BIOVENTIX PLC
Notes to the financial information
|
3.8 |
Financial instruments |
|
|
The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares. |
|
3.9 |
Creditors |
|
||||
|
Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. |
|
|||||
|
|
|
|||||
|
3.10 |
Foreign currency translation |
|
||||
|
|
|
|
||||
|
Functional and presentation currency |
|
|||||
|
The Company’s functional and presentational currency is GBP. |
|
|||||
|
|
|
|||||
|
Transactions and balances |
|
|||||
|
Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. |
|
|||||
|
|
|
|||||
|
3.11 |
Finance costs |
|
||||
|
Finance costs are charged to the Statement of comprehensive income over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument. |
|
|||||
|
|
|
|||||
|
3.12 |
Dividends |
|
||||
|
Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting. |
|
|||||
|
BIOVENTIX PLC
Notes to the financial information
|
|
|||||
|
3.13 |
Employee benefits-share-based compensation |
|
||||
|
|
The company operates an equity-settled, share-based compensation plan. The fair value of the employee services received in exchange for the grant of the options is recognised as an expense over the vesting period. The total amount to be expensed over the vesting period is determined by reference to the fair value of the options granted. At each balance sheet date, the company will revise its estimates of the number of options are expected to be exercisable. It will recognise the impact of the revision of original estimates, if any, in the profit and loss account, with a corresponding adjustment to equity. The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised. |
|
||||
|
|
|
|
||||
|
3.14 |
Research and development |
|
||||
|
|
Research and development expenditure is written off in the period in which it is incurred.
|
|
||||
|
3.15 |
Pensions |
|
||||
|
|
||||||
|
Defined contribution pension plan |
||||||
|
The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in the Statement of comprehensive income when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds. |
||||||
|
|
|
|||||
|
|
3.16 |
Interest income |
|
|||
|
Interest income is recognised in the Statement of comprehensive income using the effective interest method. |
|
|||||
|
|
|
|||||
|
3.17 |
Provisions for liabilities |
|
||||
|
Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation. Provisions are charged as an expense to the Statement of comprehensive income in the period that the Company becomes aware of the obligation, and are measured at the best estimate at the Statement of financial position date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties. When payments are eventually made, they are charged to the provision carried in the Statement of financial position. |
|
|||||
|
BIOVENTIX PLC
Notes to the financial information
|
|
|||||
|
3.18 |
Current and deferred taxation |
|
||||
|
The tax expense for the period comprises current and deferred tax. Tax is recognised in the Statement of comprehensive income, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income. |
|
|||||
|
|
|
|||||
|
Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Statement of financial position date, except that: · The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and · Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met. |
|
|||||
|
|
|
|||||
|
Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date. |
||||||
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.